# Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS

> **NCT03800524** · PHASE3 · UNKNOWN · sponsor: **Humanitas Mirasole SpA** · enrollment: 337 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** Tauroursodeoxycholic Acid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03800524
- **Lead sponsor:** Humanitas Mirasole SpA
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-22
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 337 (ACTUAL)
- **Last updated:** 2023-07-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03800524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03800524, "Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03800524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*